Since 2014, Grant Technology has privately invested in the research and development of a medical device for anti-microbial susceptibility testing; a patent was filed in January 2016 and approved, and the product launch is scheduled for early 2017.
The future of the company remains in R&D. In 2015, we invested in an ITC funded research project on a new anti-influenza drug as an industry partner with the University of Hong Kong; patents have been filed and approved. The in-vivo tests have been completed, and phase I clinical trial is expected to begin in 2018. As one of the few biotech companies established and based in the Hong Kong Science Park, we strongly believe these new developments will take our company to new heights.